NANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine
https://www.businesswire.com/news/home/20180603005066/en/
CHICAGO--(BUSINESS WIRE)--Jun 3, 2018--NANT, a technology and research company connecting breakthrough research in biology, healthcare and other areas, announced on June 3 that the Food and Drug Administration authorized clinical trials for the company’s investigational neoepitope yeast vaccine, YE-NEO-011, for a personalized, next-generation cancer immunotherapy.
The initial phase 1 clinical trial will focus on treating subjects with previously treated cancers using YE-NEO-001 in an effort to induce T-cell responses.